Michael Loney rounds up Patent Trial and Appeal Board-related decisions of note in January, including a precedential Federal Circuit decision on standing to appeal in Phigenix v ImmunoGen and two district court estoppel decisions
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
The model covers court-guided settlements, submissions-led determination of infringement and validity issues, and provides leeway for the court to determine a FRAND rate during negotiations